Kao, C., Powers, E., Datto, M. B., Green, M., Harrison, M. R., Armstrong, A. J., … Zhang, T. (2020). Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.

Kao, Chester, Eric Powers, Michael B. Datto, Michelle Green, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Jeffrey Melson Clarke, John H. Strickler, and Tian Zhang. “Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Kao C, Powers E, Datto MB, Green M, Harrison MR, Armstrong AJ, et al. Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.

Kao, Chester, et al. “Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 5, AMER SOC CLINICAL ONCOLOGY, 2020.

Kao C, Powers E, Datto MB, Green M, Harrison MR, Armstrong AJ, George DJ, Clarke JM, Strickler JH, Zhang T. Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.